SLC5A2 and type 2 diabetes mellitus: A systematic review and meta-analysis by Marilly et al. [75] (five studies, n=46,969) reported that SGLT-2 inhibitors decreased the risk of all-cause death (incidence rate ratio (IRR) 0.86 (95% CI 0.78, 0.95)), major adverse cardiovascular events (MACE) (IRR 0.91 (95% CI 0.86, 0.96)), and HHF (IRR 0.69 (95% CI 0.62, 0.76)) in individuals with T2D.